BORTEZOMIB INJECTION
Active Ingredient: BORTEZOMIB (BORTEZOMIB MANNITOL BORONIC ESTER)
Product Overview
About BORTEZOMIB INJECTION
BORETZOMIB INJECTION is a prescription medication used to treat multiple myeloma, a type of blood cancer characterized by the proliferation of malignant plasma cells in the bone marrow. It is a proteasome inhibitor that works by blocking the action of proteasomes, which are responsible for breaking down proteins in the cell.
Key Benefits & Uses
- Treatment of multiple myeloma in patients who have received at least two prior therapies
- Induction treatment of multiple myeloma in patients who are not eligible for autologous stem cell transplantation
- Relapsed multiple myeloma in patients who have received at least one prior therapy
Active Ingredient & Action
BORETZOMIB INJECTION contains the active ingredient BORTEZOMIB (BORTEZOMIB MANNITOL BORONIC ESTER), a synthetic boronic acid derivative. It works by covalently binding to the 20S proteasome, a large protein complex responsible for degrading ubiquitinated proteins. By inhibiting the proteasome, BORTEZOMIB INJECTION induces apoptosis (programmed cell death) in cancer cells, leading to a reduction in tumor size and symptoms.
Important Notes
BORETZOMIB INJECTION should be administered under the guidance of a healthcare professional. Common side effects include fatigue, nausea, diarrhea, and peripheral neuropathy. Patients with a history of cardiac disease or those taking medications that affect cardiac function should be closely monitored. It is essential to follow the recommended dosing schedule and to report any adverse reactions to a healthcare professional promptly.
Visitor ratings
Help others by rating how useful this product page is.
No ratings yet — be the first.
